| abstract |
Compositions and kits including an agent that inhibits the interaction between Disabled-2 and mutant CFTR proteins, optionally in combination with a CFTR corrector, CFTR potentiator, CAL inhibitor, mucolytic, anti- inflammatory agent or a combination thereof are provided as are methods for preventing or treating cystic fibrosis. |